Department of Molecular Biology and Genetics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.
Department of Cardiology, Functional and Ultrasound Diagnostics, Faculty of Medicine N.V. Sklifosovsky, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 119146 Moscow, Russia.
Biomolecules. 2021 Jun 29;11(7):962. doi: 10.3390/biom11070962.
Extracellular circulating microRNAs (miRNAs) are currently a focus of interest as non-invasive biomarkers of cardiovascular pathologies, including coronary artery disease (CAD) and acute coronary syndromes (ACS): myocardial infarction with and without ST-segment elevation (STEMI and NSTEMI) and unstable angina (UA). However, the current data for some miRNAs are controversial and inconsistent, probably due to pre-analytical and methodological variances in different studies. In this work, we fulfilled the basic pre-analytical requirements provided for circulating miRNA studies for application to stable CAD and ACS research. We used quantitative PCR to determine the relative plasma levels of eight circulating miRNAs that are potentially associated with atherosclerosis. In a cohort of 136 adult clinic CAD patients and outpatient controls, we found that the plasma levels of miR-21-5p and miR-146a-5p were significantly elevated in ACS patients, and the level of miR-17-5p was decreased in ACS and stable CAD patients compared to both healthy controls and hypertensive patients without CAD. Within the ACS patient group, no differences were found in the plasma levels of these miRNAs between patients with positive and negative troponin, nor were any differences found between STEMI and NSTEMI. Our results indicate that increased plasma levels of miR-146a-5p and miR-21-5p can be considered general ACS circulating biomarkers and that lowered miR-17-5p can be considered a general biomarker of CAD.
细胞外循环 microRNAs（miRNAs）目前是心血管病理学（包括冠心病（CAD）和急性冠状动脉综合征（ACS））的非侵入性生物标志物的研究热点：有和无 ST 段抬高的心肌梗死（STEMI 和 NSTEMI）和不稳定型心绞痛（UA）。然而，一些 miRNAs 的当前数据存在争议且不一致，这可能是由于不同研究中的预分析和方法学差异所致。在这项工作中，我们满足了循环 miRNA 研究的基本预分析要求，可将其应用于稳定型 CAD 和 ACS 研究。我们使用定量 PCR 来确定与动脉粥样硬化相关的 8 种循环 miRNAs 的相对血浆水平。在 136 名成年门诊 CAD 患者和门诊对照组的队列中，我们发现 ACS 患者的血浆 miR-21-5p 和 miR-146a-5p 水平显著升高，而 ACS 和稳定型 CAD 患者的 miR-17-5p 水平较健康对照组和无 CAD 的高血压患者均降低。在 ACS 患者组中，miRNAs 血浆水平在肌钙蛋白阳性和阴性患者之间、STEMI 和 NSTEMI 患者之间均无差异。我们的结果表明，miR-146a-5p 和 miR-21-5p 的血浆水平升高可被认为是一般的 ACS 循环生物标志物，而 miR-17-5p 的降低可被认为是 CAD 的一般生物标志物。
